

Review

Open Access



# Lipid-lowering therapies in patients undergoing percutaneous coronary intervention

Chan Joon Kim<sup>1,2,#</sup>, Katherine Godfrey<sup>1,#</sup>, Swagata Patnaik<sup>1</sup>, Roxana Mehran<sup>1</sup>

<sup>1</sup>The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

<sup>2</sup>Division of Cardiology, Uijungbu St. Mary's Hospital, The Catholic University of Korea, Uijungbu-si, Gyeonggi-do 11765, Republic of Korea.

<sup>#</sup>Authors contributed equally.

**Correspondence to:** Dr. Roxana Mehran, The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029, USA. E-mail: roxana.mehran@mounsinai.org

**How to cite this article:** Kim CJ, Godfrey K, Patnaik S, Mehran R. Lipid-lowering therapies in patients undergoing percutaneous coronary intervention. *Vessel Plus* 2024;8:18. <https://dx.doi.org/10.20517/2574-1209.2023.136>

**Received:** 17 Oct 2023 **First Decision:** 21 Feb 2024 **Revised:** 14 Mar 2024 **Accepted:** 26 Mar 2024 **Published:** 8 Apr 2024

**Academic Editors:** Carlos A. Mestres, Christopher Lau **Copy Editor:** Fangling Lan **Production Editor:** Fangling Lan

## Abstract

Cardiovascular disease is the leading cause of death worldwide. Over past decades, multiple clinical trials have provided substantial evidence supporting the advantages of managing plasma lipids in individuals with coronary artery disease (CAD). A primary focus in reducing clinical atherosclerotic cardiovascular disease (ASCVD) in patients who have undergone percutaneous coronary intervention (PCI) is the regulation of blood lipids, with an emphasis on low-density lipoprotein (LDL) cholesterol. Statins represent the cornerstone of lipid-lowering therapy (LLT), with high-intensity statins consistently associated with beneficial outcomes in patients at high risk of ASCVD. Nevertheless, a notable portion of patients do not achieve their target cholesterol levels through statin monotherapy, necessitating the inclusion of complementary LLT strategies. Among these therapies are ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitors, which have also demonstrated clinical advantages by further reducing cholesterol levels. Existing guidelines recommend using these agents when maximally tolerated statin doses fall short of achieving target LDL levels. Additionally, recently introduced ATP-citrate lyase inhibitors, such as bempedoic acid, have gained approval as adjunctive treatments. Furthermore, icosapent ethyl, a purified derivative of eicosapentaenoic acid, targets hypertriglyceridemia and has shown cardiovascular benefits compared to placebo. In this article, we delve into the mechanisms of blood lipids and molecular targets in connection with CAD undergoing PCI. We also explore the current landscape of available LLT options, guidelines in practice, and the subtleties of therapy.

**Keywords:** 3-hydroxy-methylglutaryl coenzyme A inhibitors, cardiovascular disease, ezetimibe, familial hypercholesterolemia, hypertriglyceridemia, icosapent ethyl, low-density lipoprotein, non-statin lipid-lowering therapies, PCSK9 inhibitors



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.



## INTRODUCTION

Cardiovascular disease persists as the predominant cause of global burden of mortality and morbidity worldwide, steadily increasing up to 19.7 million in 2019<sup>[1,2]</sup>. The cholesterol hypothesis posits that elevated blood cholesterol levels constitute a significant risk factor for atherosclerotic cardiovascular disease (ASCVD) and reducing cholesterol levels will consequently lower the risk of ASCVD<sup>[3,4]</sup>. Support for the idea that serum cholesterol plays a role in ASCVD is derived from studies on animals, genetic manifestations of hypercholesterolemia, epidemiological investigations, and randomized controlled trials. The formation of atherosclerotic, lipid-laden plaques from serum cholesterol contributes to blood vessel blockage and is ultimately responsible for the progression of cardiovascular disease.

In recent decades, outcome trials have presented substantial backing for the advantages of managing plasma lipids in individuals with coronary artery disease (CAD). Treatments aimed at lowering lipid levels have demonstrated their effectiveness in decelerating the advancement of atherosclerotic disease<sup>[5]</sup>. This finding further reinforces the pathophysiological connections between plasma lipids and the progression of CAD. Among non-lipid mechanisms involved in reducing CAD progression, lipid-lowering drugs have also been implicated in plaque stabilization, reduced inflammation, reversal of endothelial dysfunction, and decreased thrombogenicity<sup>[6]</sup>.

In this review, we will examine the available lipid-lowering therapies currently being offered to patients. We will discuss mechanisms of action, current guidelines, and nuances of therapy. Importantly, the utility of these therapies in patients with CAD undergoing percutaneous coronary intervention (PCI), particularly concerning periprocedural and long-term mortality outcomes, will be suggested. \*Note to reader: All expanded trial names can be found in [Table 1](#).

## THE MOLECULAR TARGET

### Treatment targets

Previous epidemiological investigations have revealed a connection between total cholesterol levels and the occurrence of coronary heart disease (CHD) and CHD-related mortality. Specifically, low-density lipoprotein (LDL) cholesterol has traditionally served as an assessment tool for cardiovascular risk and is frequently utilized as a surrogate marker for coronary vascular disease risk<sup>[7,8]</sup>. LDL is derived from very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and LDL remnants. Non-high-density lipoprotein cholesterol, which includes LDL, exhibits a nearly log-linear relationship with the incidence of cardiovascular disease<sup>[9]</sup>. In past decades, studies have consistently shown that reducing LDL levels significantly diminishes the risk of CHD, and it has been approximated that a 1.0 mmol/L reduction in LDL results in a 22% decrease in ASCVD risk<sup>[8]</sup>. As a result, LDL has become the primary target of lipid-lowering therapy. Current guidelines established by the American Heart Association and American College of Cardiology (AHA/ACA) and the European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) recommend LDL cholesterol (LDL-C) as an essential biomarker to set up treatment goals<sup>[9-11]</sup>. LDL-C concentrations are highly concordant with LDL particles, but in certain situations such as diabetes, obesity, or very low LDL-C, the relationship between LDL-C concentration and LDL particles is discordant. In that case, LDL particles per se determine the accurate risk of CHD<sup>[10,12-14]</sup>.

Apolipoprotein B (ApoB) is a crucial component of atherogenic lipoproteins. ApoB levels represent the concentration of the atherogenic particle in LDL, IDL, VLDL, and lipoprotein (a) independent of their

**Table 1. Major clinical trials on lipid-lowering therapy**

<b>Trial name</b>	<b>Abbreviation</b>	<b>Class</b>	<b>Population</b>	<b>Experimental arm</b>	<b>Control arm</b>	<b>Primary outcome</b>
Scandinavian simvastatin survival study <sup>[33]</sup>	4S	Statin	CHD	Simvastatin	Placebo	Mortality
Cholesterol and recurrent events <sup>[34]</sup>	CARE	Statin	MI	Pravastatin	Placebo	Fatal coronary event or a nonfatal MI
Long-term intervention with pravastatin in ischemic disease <sup>[35]</sup>	LIPID	Statin	History of AMI and UA	Pravastatin 40 mg	Placebo	Death from CHD
Osaka acute coronary insufficiency study-LIPID <sup>[37]</sup>	OACIS-LIPID	Statin	MI	Pravastatin	Placebo	Composite of death, nonfatal MI, UA, stroke
GREek atorvastatin and coronary-heart-disease evaluation <sup>[38]</sup>	GREACE	Statin	CHD	Atorvastatin 10-80 mg	Usual medical care	Death, nonfatal MI, UA, CHF revascularization, stroke
Aggressive lipid-lowering initiation abates new cardiac events <sup>[39]</sup>	ALLIANCE	Statin	Hyperlipidemia	Atorvastatin 80 mg or LDL-C < 80 mg	Usual medical care	Cardiac event
Treating to new targets <sup>[40]</sup>	TNT	Statin	CHD	Atorvastatin 80 mg or LDL-C < 80 mg	Atorvastatin 10 mg	Death from CHD, nonfatal non-procedure-related MI, resuscitation after cardiac arrest, stroke
High-Dose vs. low-dose pitavastatin in Japanese patients with stable coronary artery disease <sup>[41]</sup>	REAL-CAD	Statin	Stable CAD	Pitavastatin 4 mg	Pitavastatin 1 mg	Composite of CV death, nonfatal MI, nonfatal ischemic stroke, UA
Antihypertensive and lipid-lowering treatment to prevent heart attack trial <sup>[42]</sup>	ALLHAT-LLT	Statin	LDL 120-189 mg/dL (100-129 mg/dL if CHD)	Pravastatin	Usual medical care	All-cause mortality
High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction <sup>[43]</sup>	IDEAL	Statin	Previous MI	Atorvastatin 80 mg	Simvastatin 20 mg	Major coronary event (coronary death, nonfatal MI, cardiac arrest with resuscitation)
Reversal of atherosclerosis and aggressive lipid lowering <sup>[45]</sup>	REVERSAL	Statin	CHD	Atorvastatin 80 mg	Pravastatin 40 mg	Athoeroma volume
Myocardial ischemia reduction with aggressive cholesterol lowering <sup>[49]</sup>	MIRACL	Statin	ACS	Atorvastatin 80 mg	Placebo	Death, nonfatal MI, cardiac arrest with resuscitation or recurrent symptomatic myocardial ischemia requiring hospitalization
Aggrastat to zocor: phase Z <sup>[51]</sup>	A to Z: phase Z	Statin	ACS	Simvastatin 40 mg 1 month followed by 80 mg	Placebo 4 months followed by 20 mg simvastatin	CV death, nonfatal MI, readmission for ACS and stroke
Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial Infarction <sup>[52]</sup>	PROVE IT-TIMI 22	Statin	ACS	Atorvastatin 80 mg	Pravastatin 40 mg	Composite of death from any cause, MI, UA requiring revascularization
Atorvastatin for reduction of myocardial damage during angioplasty <sup>[53]</sup>	ARMYDA	Statin	Chronic stable angina	Atorvastatin 40 mg	Placebo	Postprocedural MI
Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-elevation myocardial infarction <sup>[56]</sup>	STATIN-STEMI	Statin	STEMI	Pretreatment of atorvastatin 80 mg	Pretreatment of atorvastatin 10 mg	Death, nonfatal MI and target vessel revascularization
Novel approaches for preventing or limiting events <sup>[57]</sup>	NAPLES II	Statin	Symptomatic CAD	Atorvastatin 80 mg	Placebo	Periprocedural MI
Rosuvastatin pretreatment in patients undergoing elective percutaneous coronary intervention to reduce the incidence of myocardial periprocedural necrosis <sup>[58]</sup>	ROMA	Statin	Stable angina	Rosuvastatin 40 mg	Standard treatment	Periprocedural myocardial necrosis

Early statin treatment in patients with acute coronary syndrome <sup>[59]</sup>	ESTABLISH	Statin	ACS	Atorvastatin 20 mg	Placebo	Change in plaque volume
Reduction of cholesterol in ischemia and function of the endothelium <sup>[60]</sup>	RECIFE	Statin	ACS	Pravastatin 40 mg	Placebo	FMD
Improved reduction of outcomes: vytorin efficacy international <sup>[61]</sup>	IMPROVE-IT	Ezetimibe	ACS	Ezetimibe 10 mg plus Simvastatin 40 mg	Simvastatin 40 mg	Composite of CV death, nonfatal MI, UA requiring rehospitalization, coronary revascularization
Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk <sup>[71]</sup>	FOURIER	PCSK9 inhibitor	ASCVD	Evolocumab plus statin	Statin	Composite of CV death, MI or stroke
Evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab <sup>[72]</sup>	ODYSSEY-OUTCOMES	PCSK9 inhibitor	ACS	Alirocumab plus statin	Statin	Composite of death from CHD, nonfatal MI, ischemic stroke, UA requiring hospitalization
Global assessment of plaque regression with a PCSK9 antibody as measured by intravascular ultrasound <sup>[78]</sup>	GLAGOV	PCSK9 inhibitor	CAD	Evolocumab plus statin	Statin	Change in PAV
Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol <sup>[86]</sup>	ORION 10, 11	PCSK9 inhibitor	ASCVD	Inclisiran plus statin	Statin	Percent change in LDL-C
Cholesterol lowering via bempedoic acid, an ACL-inhibiting regimen <sup>[88]</sup>	CLEAR	Bempedoic acid	High risk for CVD (unable to take statin)	Bempedoic acid	Placebo	CV death, nonfatal MI, nonfatal stroke, coronary revascularization
Randomized evaluation of the effects of anacetrapib through lipid modification <sup>[96]</sup>	REVEAL	CETP inhibitor	ASCVD	Anacetrapib	Placebo	Composite of coronary death, MI, coronary revascularization
Heart institute of Japan-proper level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome <sup>[113]</sup>	HIJ-PROPER	Ezetimibe	ACS	Pitavastatin plus ezetimibe	Pitavastatin	Composite of all-cause death, nonfatal MI, nonfatal stroke UA, ischemia-driven revascularization
Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia <sup>[24]</sup>	REDUCE IT	Icosapent ethyl	CVD or CV risk factors	Icosapent ethyl plus statin	Statin	Composite of CV death, nonfatal MI, nonfatal stroke, coronary revascularization or UA

ACL: ATP-citrate lyase; ACS: acute coronary syndrome; ASCVD: atherosclerotic cardiovascular disease; CAD: coronary artery disease; CHD: coronary heart disease; CVD: cardiovascular disease; FMD: flow-mediated dilatation; LDL: low-density lipoprotein; MI: myocardial infarction; PCSK9: proprotein convertase subtilisin/kexin type 9; UA: unstable angina.

cholesterol content. Indeed, it has been demonstrated that the number of serum ApoB particles present within the arterial wall is linked to the risk of cardiovascular disease. Therefore, cardiovascular risk may be more directly associated with the quantity of ApoB particles than the amount of cholesterol they contain<sup>[15,16]</sup>. This has led to the argument that ApoB may serve as a better indicator of cardiovascular risk compared to other cholesterol<sup>[17]</sup>. In line with this, the 2019 guidelines established by ESC/EAS outlined the usefulness of ApoB as a more precise marker of cardiovascular risk compared to other cholesterol and presented ApoB levels as one of the treatment targets of lipid management in ASCVD including patients undergoing PCI<sup>[10]</sup>.

There has also been a demonstrated correlation between elevated triglycerides (TG) and an increased risk of cardiovascular disease (CVD)<sup>[18,19]</sup>. However, it is unclear whether hypertriglyceridemia directly causes CVD, or if triglycerides act as a proxy for coexisting metabolic derangements<sup>[20]</sup>. Elevated serum triglyceride levels can result from isolated increases in chylomicron concentration, an upsurge in the triglyceride content of VLDL, or a rise in the total number of circulating VLDL particles. Consequently, hypertriglyceridemia should be regarded as a non-specific condition, possibly entailing varying degrees of

cardiovascular risk<sup>[21]</sup>. Nonetheless, TG and TG-rich lipoprotein (TGRL) are regarded as major contributors to ASCVD risk even in patients who achieved guideline-recommended LDL levels, and a reduction in serum triglycerides has been linked to an additional reduction of significant cardiovascular events<sup>[22,23]</sup>. As a result, potential therapeutic benefits remain associated with medications such as icosapent ethyl (IPE), fibrates, and omega-3 fatty acids. Notably, the use of IPE exhibited a significant reduction in ischemic events among individuals who have established ASCVD and elevated triglycerides, as discussed later in this review<sup>[24]</sup>.

## LIPID-LOWERING THERAPIES

### Non-pharmacologic interventions

Non-pharmacological management of dyslipidemia plays a crucial role in both primary and secondary prevention. The National Cholesterol Education Program (NCEP) guidelines outline three key pillars of non-pharmacological management, which include dietary adjustments, physical activity, and weight maintenance. These interventions have the potential to serve as effective treatments for as many as 90% of patients affected by dyslipidemia<sup>[25]</sup>. Various nutrients have been associated with pro-atherosclerotic risk factors, such as hypertension, obesity, and dyslipidemia<sup>[26]</sup>. Elevated cholesterol levels are often a result of increased consumption of saturated fats and dietary cholesterol. Research has demonstrated that regular consumption of foods rich in saturated fats leads to higher levels of LDL cholesterol in the bloodstream, coupled with an increase in high-density lipoprotein (HDL) levels<sup>[27]</sup>. In contrast, unsaturated fats tend to improve the lipid profile by reducing LDL levels, with minimal effects on HDL<sup>[10]</sup>. The NCEP Step I and Step II dietary plans have been designed to progressively decrease the consumption of calories and saturated fats, thereby reducing lipoprotein levels and enhancing weight loss. The significance of dietary modifications should be underscored, as even a 1.0 mmol/L reduction in low-density cholesterol can potentially lower an individual's risk of developing CAD by 20%<sup>[10,28]</sup>.

In addition to cutting down on saturated fat intake, increasing the consumption of soluble fiber has been demonstrated to reduce both total cholesterol and LDL cholesterol levels. An additional 3 grams of soluble fiber per day may potentially reduce total cholesterol by 5-6 mg/dL. The AHA diet, which places an emphasis on dietary fiber, has the potential to lower total cholesterol by 11%-32%. Furthermore, a diet high in carbohydrates and fiber can help lower serum triglyceride levels while elevating HDL levels<sup>[10]</sup>.

Exercise is another essential element in the management of dyslipidemia. Most patients can benefit from engaging in aerobic exercise for at least 30 min, a minimum of four times per week<sup>[10]</sup>.

In the same vein, the NCEP also advocates weight loss as a fundamental component of cholesterol management. Research has shown that a 5%-10% reduction in body weight can lead to improvements in cardiovascular risk factors by lowering triglycerides, total cholesterol, and LDL cholesterol. Additionally, individuals who lose more than 10% of their body weight experience even more significant reductions in serum lipids and a potential elevation in HDL cholesterol. Moreover, various lifestyle changes can impact atherogenesis and cardiovascular risk factors. The AHA underscores the importance of quitting smoking and vaping, as these habits have been linked to decreased HDL levels and its function, increasing the risk of cardiovascular disease<sup>[9]</sup>.

Atherogenesis is known to be partially influenced by the oxidation and glycosylation of LDL cholesterol. Consequently, antioxidants, such as vitamin C, E, and beta-carotene, may offer some protection against atherogenesis<sup>[29]</sup>.

## Lipid-lowering drug therapies

### *Statins-mechanism of action and cardiovascular benefits*

Statins represent one of the most extensively studied drug classes in randomized controlled trials. They function by reducing LDL cholesterol levels through the inhibition of 3-hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase, a mechanism known for its role in curbing the growth and instability of coronary plaques, ultimately lowering the risk of major cardiovascular events. Statins have also been implicated in improving endothelial function and reducing inflammation and thrombogenicity<sup>[10]</sup>.

The safety and efficacy of commonly used statins, which include atorvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin, are well-established. While all statins operate through a shared mechanism, there are slight variations in their pharmacokinetic properties and susceptibility to interactions. Statins are categorized based on their intensity, which can differ depending on the dosage. High-intensity statins achieve LDL reductions of 50% or more, while moderate-intensity statins result in a 30%-60% LDL reduction, and low-intensity statins, a less than 30% reduction<sup>[9,10,30]</sup>. Statins categorized by intensity and dosage can be visualized in [Table 2](#)<sup>[9,10]</sup>.

More intensive statin therapy has been associated with an increased side effect profile<sup>[31,32]</sup>. A meta-analysis from 135 randomized controlled trials examined the tolerability of various statins<sup>[31]</sup>. This analysis found that simvastatin and pravastatin had the lowest likelihood of causing myalgia, elevated transaminases, and creatine kinase (CK) elevation compared to other statins. With regards to transaminitis, pravastatin, rosuvastatin, and simvastatin demonstrated a reduced likelihood of transaminase elevation, while atorvastatin and fluvastatin showed higher odds. The analysis also revealed that, as a class, statins did not significantly differ from control groups in terms of CK elevation. However, at the meta-analysis level, statins as a class exhibited a statistically significant association with the incidence of diabetes mellitus compared to placebo. Pravastatin and simvastatin emerged as the statins with the most favorable profile in terms of tolerability and side effects<sup>[31]</sup>.

Historically, the 4S study marked a pivotal moment as the first large-scale randomized controlled trial to showcase a reduction in major cardiovascular events, cardiovascular mortality, and overall mortality in individuals with CAD and elevated cholesterol levels who were administered simvastatin, compared to those given placebo<sup>[33]</sup>. Following this landmark trial, the CARE trial demonstrated the protective effects of 40 mg pravastatin, compared to a placebo, in patients who had experienced a myocardial infarction (MI) and had average cholesterol levels<sup>[34]</sup>. The LIPID trial also unveiled the durable benefits of lowering LDL in patients with a wide spectrum of cholesterol levels and a history of MI or unstable angina (UA). This reduction ultimately decreased mortality risk from CHD and all-cause death<sup>[35]</sup>.

Likewise, the MRC/BHF Heart Protection Study illustrated a notable decrease in the incidence of major vascular events in a diverse group of high-risk individuals who took 40 mg of simvastatin compared to placebo. This included statistically significant reductions in all-cause mortality, coronary death rate, nonfatal MI or coronary deaths, nonfatal or fatal strokes, and coronary or non-coronary revascularization. Importantly, these benefits were observed irrespective of initial cholesterol levels<sup>[36]</sup>. Another study showed a notable reduction in recurrent major adverse cardiac events (MACE), including death, nonfatal MI, UA, stroke, revascularization, and rehospitalization. This reduction was observed in patients with acute MI who were administered 10 mg of pravastatin compared to those receiving non-statin lipid-lowering drugs. The event rate was 17.9% in the statin group and 31.4% in the control group. Additionally, the statin group exhibited a 22% reduction in LDL from baseline, compared to a 6% reduction in the control group<sup>[37]</sup>.

**Table 2. High-, moderate-, and low-intensity statin therapy by dosage**

Strength	Name	Dose
High-intensity	Atorvastatin	40-80 mg
	Rosuvastatin	20-40 mg
Moderate-intensity	Atorvastatin	10-20 mg
	Fluvastatin	40 mg (or XL 80 mg)
	Lovastatin	40-80 mg
	Pitavastatin	1-4 mg
	Pravastatin	40-80 mg
	Rosuvastatin	5-10 mg
	Simvastatin	20-40 mg
Low-intensity	Fluvastatin	20-40 mg
	Lovastatin	20 mg
	Pravastatin	10-20 mg
	Simvastatin	10 mg

### *Intensity of statins*

The utilization of moderate- and high-intensity statins has been proven to yield significant clinical benefits across a wide spectrum of patients compared to low-intensity therapy. Findings from the GREACE study emphasized that the treatment of CHD patients with atorvastatin (primarily 20 mg atorvastatin) to attain NCEP lipid targets (less than 100 mg/dL) is not only safe but also leads to a substantial decrease in total mortality, as well as coronary mortality and morbidity and stroke, compared to standard care involving non-statin lipid-lowering drugs. In this study, patients who received atorvastatin, with doses titrated to achieve an LDL goal of less than 100 mg/dL ( $< 2.586$  mmol/L) among CHD patients, experienced a statistically significant reduction in primary endpoints (indicative of coronary morbidity and mortality). Importantly, there was a statistically significant mean LDL difference between the intervention and control groups by the end of the follow-up period, with an LDL reduction from baseline of 46% in the treatment group compared to 5% in the control group<sup>[38]</sup>.

Several trials have also demonstrated that achieving lower LDL levels is associated with fewer MACE in patients with pre-existing CHD. The ALLIANCE study, involving 2,442 CHD patients with comorbid hyperlipidemia, initiated either an aggressive atorvastatin regimen titrated to achieve an LDL goal of less than 80 mg/dL (2.069 mmol/L) or a maximum daily dose of 80 mg, as opposed to receiving usual care (other non-statin lipid-lowering drugs). Their result showed that both the time to adverse cardiovascular events (high-intensity atorvastatin vs. usual care, 23.7% vs. 27.7%) and LDL cholesterol levels (atorvastatin vs. usual care, 34.3% vs. 23.3%) may be reduced with an aggressive atorvastatin regimen<sup>[39]</sup>. Likewise, the TNT trial showed that employing intensive atorvastatin therapy to reduce LDL levels below 100 mg/dL correlates with considerable clinical benefits in patients with stable CHD<sup>[40]</sup>. The REAL-CAD trial also demonstrated a significant reduction in MACE with higher-intensity statins in Asian populations<sup>[41]</sup>.

Interestingly, some trials failed to show a significant reduction in MACE when comparing patients on statins to those without lipid-lowering therapy, even when there was a significant reduction in LDL cholesterol levels. For instance, the ALLHAT-LLT study, comparing pravastatin 40 mg vs. placebo, revealed the efficacy of statins in patients with stage 1 or 2 hypertension and at least one additional CHD risk factor. The study demonstrated that adherence to pravastatin resulted in a 28% reduction in LDL levels from



baseline, compared to an 11% reduction in the control group. However, dissimilar to previous trials, no reduction in total mortality was observed<sup>[42]</sup>. The IDEAL study was also unable to establish a statistically significant reduction in MACE in patients taking high-intensity statins despite a significant 49% reduction in LDL concentration compared to the moderate-intensity group<sup>[43]</sup>. However, in a meta-analysis from Cholesterol Treatment Trialist Collation (CTT) comprising 26 RCTs evaluating high- vs. moderate-intensity statin therapy, more intensive regimens produced a significant 15% reduction in major vascular events. Additionally, the cardiovascular benefits per 1.0 mmol/L reduction in LDL cholesterol were similar to findings from previous statin vs. control trials<sup>[44]</sup>.

#### *Stable CAD and acute coronary syndrome*

The use of high-intensity statins not only reduces the occurrence of periprocedural myocardial necrosis and risk of MACE but also hinders the progression of atherosclerosis. This effect on atherosclerosis has been observed in patients with stable CAD as well as in those who have undergone coronary artery bypass graft (CABG) surgery<sup>[45,46]</sup>. Additionally, this reduced rate of atherosclerosis has been linked to decreased carotid intimal-medial thickening<sup>[47,48]</sup>.

The REVERSAL study utilized intravascular ultrasound (IVUS) to assess the advancement of atherosclerosis in 654 CAD patients undergoing coronary angiography. These patients were either on an intensive statin regimen (atorvastatin 80 mg) or a moderate-intensity regimen (pravastatin 40 mg). The study revealed that coronary atherosclerosis progressed in the pravastatin group by a 2.7% increase, while no progression was observed in the atorvastatin group (0.4% decrease without statistical significance) compared to the baseline measurements<sup>[45]</sup>.

Previous trials have demonstrated that initiating statin therapy in the post-acute coronary syndrome (ACS) period has a role in reducing the incidence of post-ACS MACE. The MIRACL study, for example, revealed that treatment with atorvastatin 80 mg daily, initiated during the acute phase of UA or non-Q wave MI, leads to a reduction in the risk of early recurrent ischemic events. The reduction was notable compared to a placebo, with a 16 week follow-up showing rates of 14.8% in the atorvastatin group vs. 17.4% in the placebo group<sup>[49]</sup>. In addition, the follow-up to the Extended-ESTABLISH study showed that the in-hospital initiation of statins promptly following an ACS event provides longstanding benefits, particularly in reducing the occurrence of major adverse cardiac and cerebrovascular events (MACCE). The atorvastatin group displayed significantly higher cumulative event-free survival than the control group (lipid-lowering diet).

Early statin administration was also identified as a strong predictor of MACCE<sup>[50]</sup>. The importance of early statin initiation was further underscored by the A to Z: Phase Z trial. A comparison of early initiation of an intensive statin regimen to delayed initiation of a less-intensive regimen in ACS patients indicated that early initiation resulted in a reduction in MACE, although it did not reach statistical significance (simvastatin vs. placebo, 14.4% vs. 16.7%)<sup>[51]</sup>. The PROVE IT-TIMI 22 trial provided further evidence that, with early initiation of high-intensity statin after ACS, patients experience an increased significant reduction in MACE when their target LDL level is set lower than the original guideline target of 100 mg/dL. In this trial, high-dose atorvastatin (80 mg) compared to standard-dose pravastatin (40 mg) reduced the hazard ratio for MACE by 16%<sup>[52]</sup>.

#### *Timing of statin in PCI*

The implementation of higher-intensity statins in the pre-procedural period has also been shown to enhance clinical outcomes. The first of the ARMYDA series of trials demonstrated that in patients with



stable angina, pretreatment with atorvastatin at a daily dose of 40 mg for one week prior to coronary intervention can reduce the occurrence of periprocedural MI compared to placebo<sup>[53]</sup>. Furthermore, the ARMYDA-ACS trial revealed that short-term pretreatment with atorvastatin before PCI leads to improved clinical outcomes in patients with UA and non-ST-segment elevation myocardial infarction (NSTEMI). Patients who received a 12-h pretreatment dose of atorvastatin at 80 mg, followed by an additional pre-procedure dose, exhibited a statistically significant reduction in periprocedural and post-PCI MACE compared to those who received a placebo<sup>[54]</sup>. Finally, the ARMYDA-RECAPTURE trial showed that a short-term, high-dose atorvastatin pre-load before PCI improves outcomes during and after PCI in patients who are already on long-term statin therapy. Patients receiving a 12-h pretreatment dose of atorvastatin at 80 mg before the intervention, along with an additional 40 mg pre-procedural dose, experienced a significant decrease in MACE following PCI, compared to those who received pre-procedural placebo prior to intervention, followed by treatment with atorvastatin 40 mg after the index procedure<sup>[55]</sup>.

In addition to the ARMYDA series of trials, the STATIN-STEMI trial demonstrated increased myocardial perfusion in ST-elevation myocardial infarction (STEMI) patients undergoing PCI. While the STATIN-STEMI trial did not show a significant reduction in MACE in patients taking pre-procedural atorvastatin at 80 vs. 10 mg, it is worth noting that the corrected thrombolysis in myocardial infarction (TIMI) frame count was significantly reduced in the atorvastatin 80 mg compared to 10 mg group (26.9% vs. 34.1%)<sup>[56]</sup>.

The NAPLES II trial also offered evidence supporting the cardioprotective effect of a single loading dose of high-intensity atorvastatin (80 mg) given within 24 h of stent placement. In individuals who had not previously taken statins, the administration of a pretreatment dose of atorvastatin 80 mg before elective PCI, as compared to no statin pretreatment, was linked to a statistically significant reduction in the incidence of periprocedural MI (9.5% vs. 15.8%)<sup>[57]</sup>.

Other high-intensity statins, particularly rosuvastatin, have also demonstrated their effectiveness in reducing periprocedural MI, as evident in the results of the ROMA trial. The ROMA study revealed that a single high-intensity loading dose of rosuvastatin at 40 mg within 24 h of elective PCI significantly reduces the occurrence of periprocedural MI at both the 12- and 24-h marks after intervention compared to standard care (non-statin lipid-lowering therapy)<sup>[58]</sup>.

Additionally, the ESTABLISH trial provided evidence that in patients with ACS undergoing emergent PCI, early and aggressive lipid-lowering therapy using atorvastatin for 6 months leads to a significant reduction in plaque volume, as measured by IVUS, in comparison to the control group (13.1% decrease vs. 8.7% increase). Furthermore, the atorvastatin group experienced a substantial reduction in LDL cholesterol compared to standard care (-41.7% vs. 0.7%)<sup>[59]</sup>.

The impact of statins on the improvement of endothelial function following ACS has been demonstrated in the RECIFE trial. In patients with acute MI or UA and elevated total and LDL cholesterol levels, endothelium-dependent flow-mediated dilatation (FMD) was measured after treatment with either placebo or pravastatin at 40 mg for 6 weeks. In this study, FMD showed a notable increase in the pravastatin group (from 4.93% to 7.0%), whereas the placebo group did not exhibit such significant changes. The pravastatin group showed a significant reduction in total (23% decrease) and LDL (33% decrease) cholesterol levels, but not in the placebo group<sup>[60]</sup>.

### *Ezetimibe*

As mentioned earlier, the addition of ezetimibe to a statin regimen has proven effective in achieving lower cholesterol and reducing the risk of cardiovascular disease. The IMPROVE-IT trial, which included about 70% of patients who underwent PCI, provided compelling evidence for the incorporation of ezetimibe into statin therapy. For stable patients who had recently experienced an ACS event, and whose LDL levels fell within guideline recommendations, ezetimibe plus simvastatin 40 mg led to a further reduction in LDL levels and MACE compared to simvastatin alone<sup>[61]</sup>. Another study evaluating the effect of ezetimibe in elderly patients ( $\geq 75$  years old) with no prior cardiovascular history, indicated that reduction of LDL cholesterol with ezetimibe contributed to the prevention of cardiovascular events in the elderly population<sup>[62]</sup>. In a comprehensive systematic review and meta-analysis, substantial evidence supports the efficacy of ezetimibe in reducing ASCVD risk and suggests that moderate-density statin plus ezetimibe combination therapy may be more effective and safe than high-intensity statin in terms of reduction of LDL cholesterol and statin-related adverse effect<sup>[63,64]</sup>.

### *PCSK9 inhibitors*

In addition to statin and ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors play a crucial role in regulating cholesterol metabolism. PCSK9 binds to low-density lipoprotein receptors (LDLR) on hepatocytes, promoting LDLR degradation in the liver, thereby increasing serum LDL levels. Increased PCSK9 activity has been associated with elevated LDL cholesterol levels. Indeed, familial hypercholesterolemia (FH) has been linked to gain-of-function mutations in PCSK9<sup>[65,66]</sup>. Conversely, a reduction in PCSK9 function has been linked with lower cholesterol levels and, in turn, a reduced risk of cardiovascular disease<sup>[67]</sup>. PCSK9 inhibitors prevent PCSK9 from binding to LDL, leading to a decrease in circulating LDL levels<sup>[68]</sup>.

Alirocumab is a human monoclonal immunoglobulin of the G1 isotype, while evolocumab belongs to the G2 isotype. Both act to bind to human PCSK9, leading to a reduction in LDL<sup>[68,69]</sup>. Both alirocumab and evolocumab are administered as subcutaneous injections with the indication of reducing the risk of MI and cerebrovascular accident (CVA). They share a similar safety profile, although a comprehensive meta-analysis has indicated that alirocumab is associated with a higher risk of injection site reaction than evolocumab<sup>[70]</sup>. A number of significant trials have provided substantial evidence for both the short-term and long-term advantages of alirocumab and evolocumab in reducing the occurrence of cardiovascular events. The FOURIER trial illustrated the cardiovascular benefits of lowering LDL cholesterol levels below existing targets. Particularly, when administered in conjunction with statin therapy, evolocumab reduced LDL levels to a median of 30 mg/dL and the risk of MACE by 15% in patients with pre-existing CAD, compared to placebo<sup>[71]</sup>. The ODYSSEY-OUTCOMES study further showcased the effectiveness of alirocumab in individuals with a recent history of ACS (PCI or CABG performed in about 71%) whose atherogenic lipoprotein levels remained elevated, despite treatment with either high- or maximum-dose statin therapy. In this trial, alirocumab exhibited lower MACE rates compared to the placebo group (9.5% vs. 11.1%)<sup>[72]</sup>. Subsequent trials within the ODYSSEY series have provided further insight into the efficacy of PCSK9 inhibitors in high-risk ASCVD patients in reducing cardiovascular disease risk and cholesterol levels, all while maintaining a well-tolerated side effect profile<sup>[73-76]</sup>. These effects have also been observed in patients with type 2 diabetes mellitus (T2DM) and mixed dyslipidemia, even when receiving maximum statin therapy, in comparison to usual care (non-statin lipid-lowering therapies)<sup>[77]</sup>.

The GLAGOV trial, encompassing 968 CAD patients, showed significantly greater LDL cholesterol lowering and atheroma regression in patients taking PCSK9 inhibitors compared to placebo. Patients on an evolocumab regimen combined with a pre-existing statin achieved markedly lower LDL levels

(-56.6 mg/dL) and a substantial reduction in percent atheroma volume (PAV) (-1.0%)<sup>[78]</sup>.

Moreover, as with the prompt initiation of statins after ACS, the immediate commencement of PCSK9 inhibitors alongside high-intensity statin therapy has also demonstrated a significant decrease in LDL cholesterol levels compared to statin therapy alone<sup>[79]</sup>.

Another extensive meta-analysis provides compelling data supporting the effectiveness of both alirocumab and evolocumab in reducing MACE<sup>[80]</sup>. In a systematic review of randomized trials on non-statin lipid-lowering therapies, both alirocumab and evolocumab have demonstrated efficacy in improving lipid levels, but alirocumab appears to be more effective in patients at high cardiovascular risk who have not achieved their LDL goals. Evolocumab has shown superior efficacy in patients with heterozygous FH. However, when HDL levels were analyzed, it was determined that both evolocumab and alirocumab resulted in a moderate increase in HDL from baseline compared to placebo and ezetimibe<sup>[81]</sup>.

Inclisiran, on the other hand, is a small interfering double-stranded RNA (siRNA) that specifically inhibits the hepatic production of PCSK9. The antisense strand of inclisiran corresponds to human PCSK9 mRNA. Incrisiran is conjugated with triantennary N-acetylgalactosamine carbohydrates (tri-GalNAC) to bind asialoglycoprotein receptors on the surface of hepatocytes. This enables uptake of the drug, and in the hepatocyte, inclisiran binds to the RNA-silencing complex (RISC) to cleave the mRNA encoding PCSK9. This consequently lowers serum LDL cholesterol levels<sup>[82]</sup>.

Inclisiran has proven its efficacy in reducing LDL cholesterol levels in phase 1 and phase 2 trials, with reductions ranging from 27.9% to 41.9% with a single dose and 35.5% to 52.6% with two doses, all without serious adverse events<sup>[83]</sup>. In the ORION-10 and -11 trials, two pivotal phase-III clinical trials, inclisiran reduced LDL levels by 52.3% (ORION-10) and 49.9% (ORION-11) in patients with ASCVD who were already on maximum statin monotherapy<sup>[84,85]</sup>. A pooled analysis of ORION-9, -10, and -11 confirmed that 61.5% of inclisiran recipients achieved a reduction in LDL cholesterol of 50% or more, in contrast to only 2.2% of patients taking a placebo by 15 months. Additionally, there were significant reductions in ApoB, lipoprotein a [Lp(a)], triglyceride levels, and most importantly, the incidence of MACE<sup>[86]</sup>.

#### *ATP citrate lyase inhibitors*

Beyond PCSK9, another crucial enzyme in cholesterol synthesis, ATP citrate lyase (ACL), has come into focus. In the United States, bempedoic acid, an inhibitor of ACL, has received approval for use as an adjunctive therapy to lower LDL cholesterol levels in patients with ASCVD who do not achieve their target LDL goals with statins. It has also gained approval as a primary prevention method for patients with FH<sup>[87]</sup>.

The effectiveness of bempedoic acid as a lipid-lowering treatment has been recently revealed, particularly for patients who are intolerant to statins. The CLEAR trial, a large-scale study, demonstrated that bempedoic acid leads to a more substantial reduction in LDL cholesterol levels compared to placebo at both 6- (21.7% vs. 0.6%) and 60-month intervals (26.1% vs. 10.6%). Additionally, this study indicated a significant reduction in MACE when comparing the effects of bempedoic acid to placebo (11.7% vs. 13.3%). It is worth noting that bempedoic acid is linked to a lower incidence of myositis, making it a viable treatment alternative for patients who cannot tolerate this adverse statin effect<sup>[88]</sup>.

#### *Eicosapentaenoic Acid and Icosapent Ethyl*

Icosapent ethyl is a purified derivative of eicosapentaenoic acid (EPA), which has been studied as a treatment for reducing cardiovascular risk in individuals with hypertriglyceridemia. Two multicenter,

randomized clinical trials have shown that IPE effectively lowers triglyceride levels, although these studies did not analyze cardiovascular outcomes<sup>[89]</sup>.

The REDUCE-IT study aimed to assess the ability of IPE to reduce cardiovascular risk in a patient population with established risk factors who were already taking statins. Results from this study demonstrated that IPE reduced the risk of MACE by 25% compared to placebo<sup>[24]</sup>. Furthermore, the EVAPORATE study investigated whether the addition of IPE in patients with hypertriglyceridemia could lead to a reduction in the volume of coronary atheromatous plaques. These patients were already on statin monotherapy and observing dietary modifications. Its results showed a significant decrease in the volume of low attenuation plaques in the group receiving IPE therapy after 18 months of the study<sup>[90]</sup>. It has been suggested that EPA and IPE may achieve this through reduction of serum triglycerides, antiplatelet effects, anti-inflammatory and antioxidant properties, lipid membrane stabilization and inhibition of lipid oxidation<sup>[91]</sup>. IPE may also play a role in lowering remnant lipoproteins (RLP), which are highly atherogenic. The ANCHOR and MARINE studies provided evidence of IPE's efficacy in decreasing RLP levels by up to 30% compared to placebo<sup>[89]</sup>.

## Other therapies

### *Fibrates*

Fibrates function by stimulating the uptake of cellular fatty acids by enhancing their conversion into acyl-CoA derivatives and subsequent catabolism through the beta-oxidation pathways. This process leads to a decrease in the production of VLDL and a reduction in the synthesis of triglycerides<sup>[92]</sup>. An extensive meta-analysis involving patients receiving treatment with fibrates indicated a decreased risk of MACE compared to placebo. However, the absolute benefits of fibrate therapy in the context of primary prevention were relatively modest<sup>[93]</sup>.

### *Bile acid sequestrants (cholestyramine and colestipol)*

Bile acid sequestrants function by capturing bile acids within the intestine, which disrupts their enterohepatic circulation, prevents their resorption, and increases their excretion in the feces. Furthermore, the reduction in the amount of bile acids transported back to the liver triggers the upregulation of hepatic cholesterol cytochrome CYP7A1. This, in turn, promotes the conversion of cholesterol into bile acids, further decreasing intrahepatic cholesterol. A meta-analysis focusing on bile acid sequestrants has revealed that these agents may serve as a complementary therapy with LDL-lowering benefits, especially in patients who cannot tolerate high-dose statins<sup>[94]</sup>.

### *CETP inhibitors*

Cholesterol ester transfer protein (CETP) is another protein involved in the transportation and formation of LDL. Its role is to transfer cholesterol esters (CE) from HDL to both VLDL and LDL. Inhibitors targeting CETP have been proven to markedly decrease LDL while increasing HDL<sup>[95]</sup>.

However, the application of CETP inhibitors at present is limited due to their inadequate efficacy and safety concerns. More recently, in a phase-II trial, obicetrapib, used as an adjunct to high-intensity statins, displayed a significant reduction in LDL and non-HDL cholesterol levels with an acceptable safety profile<sup>[96]</sup>. A phase-III trial of obicetrapib is currently underway to assess its effectiveness and safety in individuals with heterozygous FH and ASCVD.

### *Mipomersen and lomitapide*

Mipomersen and lomitapide have received approval for the treatment of FH<sup>[97,98]</sup>. Mipomersen, a second-generation antisense oligonucleotide, is complementary to human ApoB-100 mRNA. Administered subcutaneously, mipomersen operates primarily in the liver by binding to ApoB-100 mRNA. This mRNA binding leads to the inhibition of protein translation, resulting in reduced production of LDL, VLDL, and Lp(a)<sup>[99]</sup>. An analysis conducted post-hoc from three randomized clinical trials indicated a potential reduction in MACE in FH patients, which coincided with a significant decrease in LDL levels<sup>[100]</sup>.

On the other hand, lomitapide acts as a microsomal triglyceride transfer protein inhibitor, impeding the formation of lipoproteins containing apoB in both the liver and intestines. Clinical investigations have indicated that lomitapide can reduce LDL levels ranging from 35% to 88%<sup>[101-104]</sup>. While the prescription of lomitapide is constrained by gastrointestinal side effects, including the development of hepatic steatosis, it is generally better tolerated than mipomersen, especially due to the absence of injection site reactions<sup>[98]</sup>. In a multicenter, retrospective, observational study, the utilization of lomitapide in FH patients was linked to a three-fold reduction in the occurrence of MACE, although this difference did not attain statistical significance<sup>[105]</sup>. Mipomersen and lomitapide are specifically reserved for patients who have FH and uncontrolled LDL despite statin therapy.

## **GUIDELINES (ACC/AHA AND ESC)**

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol recommends high-intensity statins, capable of reducing LDL levels by 50% or more, in individuals with ASCVD who are 75 years old or younger and not at very high risk. If statin therapy fails to reach a 50% reduction in LDL, additional lipid-lowering therapy, such as ezetimibe, can be used. For those over the age of 75, the decision is based on a careful assessment that considers the potential for reducing ASCVD risk, the patient's frailty, preferences, and potential adverse effects. Depending on this evaluation, either moderate- or high-intensity statins may be prescribed. Patients with ASCVD at very high risk should be prescribed high-intensity statins regardless of their age, and ezetimibe and PCSK9 inhibitors can be added to the statin regimen<sup>[9]</sup>. In the United States, alirocumab and evolocumab, and inclisiran have been approved by the FDA for use<sup>[106]</sup>.

On the other hand, the 2019 ESC/EAS Guidelines for the Management of Dyslipidemias propose targeting an LDL level of 55 mg/dL or lower, as well as achieving a reduction of greater than 50% from baseline for patients at very high risk, including those with established ASCVD (previous ACS, stable angina, coronary revascularization) who require secondary prevention<sup>[11]</sup>. An even more stringent target of less than 40 mg/dL is recommended for individuals who have experienced recurrent cardiovascular events within two years<sup>[45]</sup>. In ACS patients, it is recommended to immediately start high-intensity statins regardless of initial LDL-C level and follow up within 4-6 weeks. If the LDL-C goal is not achieved, ezetimibe and PCSK9 inhibitors should be added sequentially. The latest NCEP III and ACC/AHA guidelines advocate for an LDL target of less than 70 mg/dL for individuals with diagnosed CAD or its equivalents<sup>[107]</sup>.

## **PRACTICAL APPROACH**

For patients undergoing PCI, it is advisable to consider pretreatment or a loading dose of high-intensity statins, particularly in elective cases or in those presenting with UA or NSTEMI. Even in patients with STEMI, there can be potential benefits from a loading dose of high-intensity statins. High-intensity statin therapy should be maintained after the procedure unless there are contraindications. Since a significant number of patients do not achieve their target LDL levels with statin monotherapy, a sequential approach involving the addition of ezetimibe, followed by PCSK9 inhibitors, is recommended<sup>[4]</sup>. Recent studies indicate that the initial combination therapy of statins with ezetimibe or statins with ezetimibe and PCSK9



inhibitors can be advantageous for very high-risk patient groups, as the cardiovascular benefits appear to be independent of the specific lipid-lowering mechanism<sup>[108,109]</sup>.

In cases where statin intolerance is observed, ACL inhibitors like bempedoic acid can be considered. If PCSK9 inhibitors are indicated but self-injection is not well-tolerated, inclisiran can serve as an alternative. For patients with familial hypercholesterolemia, lomitapide or mipomersen may be considered as treatment options in addition to PCSK9 inhibitors.

For individuals aged over 75 who have undergone PCI but are not considered at high risk for ASCVD, it is appropriate to begin treatment with moderate-intensity statins. If the LDL cholesterol levels do not reach the target goal with this regimen, the addition of ezetimibe can be considered. In individuals who are high-risk ASCVD patients and less than 75 years old, the preferred approach is to initiate high-intensity statin therapy. If patients experience intolerance to high-intensity statins, a regimen involving moderate- or low-intensity statins, coupled with ezetimibe, can be employed.

In both of these patient groups, the inclusion of bempedoic acid can be considered if the desired LDL cholesterol target is not attained. For patients with triglyceride levels exceeding 135 mg, icosapent ethyl may be a suitable option.

Lipid-lowering medications often interact with other drugs. Statins rely on the cytochrome-p (CYP) 450 system for their metabolism, as well as organic anion transporting polypeptide (OATP), breast cancer resistance protein (BCRP), or P-glycoproteins. Inhibitors of the CYP3A4 system (such as azole antifungals and protease inhibitors) pose an elevated risk of statin-related side effects, particularly for atorvastatin, lovastatin, and simvastatin. Calcium channel blockers (like amlodipine, verapamil, and diltiazem) moderately inhibit these enzymes and should be used with caution<sup>[110]</sup>. Ticagrelor may also increase the levels of certain statins in the blood, including atorvastatin and simvastatin<sup>[111]</sup>.

Pitavastatin, pravastatin, and rosuvastatin are primarily excreted such that their blood concentrations are not substantially affected by CYP3A4 inhibitors. Fluvastatin is metabolized by the CYP2C9 system, and its blood levels can be influenced by inhibitors of this enzyme. Gemfibrozil inhibits CYP2C8 and OATP1B1, so the combination of gemfibrozil and statins is not recommended due to an increased occurrence of muscle-related side effects. Fenofibrate may intensify the adverse effects of statins, making close monitoring necessary when initiating this combination.

Bempedoic acid raises the blood concentration of pravastatin and simvastatin. Consequently, doses of pravastatin exceeding 40 mg and simvastatin greater than 20 mg are not recommended in combination with bempedoic acid. When using icosapent ethyl and omega-3 acid derivatives, it is important to be aware that they may prolong bleeding time in patients taking antithrombotic agents<sup>[112]</sup>.

### **Perspectives**

Current guidelines for LLT primarily rely on data from large-scale randomized controlled trials involving patients who had CAD and received statin therapy. However, there is still a notable absence of data that would help determine whether there is a lower limit for the desired LDL cholesterol level, below which the benefits of LLT become less apparent. Future research is also necessary to investigate the advantages of non-statin therapies in terms of long-term cardiovascular outcomes and specific patient populations, such as those with advanced chronic kidney disease (CKD) or end-stage renal disease (ESRD), individuals with chronic inflammatory conditions, recipients of organ transplants, older patients (aged 75 and above), and



pregnant patients. Moreover, there is a need to address the optimal timing for initiating LLT or introducing non-statin therapies in patients who have undergone PCI.

## CONCLUSION

Lipid-lowering medications have shown their effectiveness in decreasing mortality rates among patients with diverse initial cholesterol levels and individuals who have pre-existing CAD and underwent PCI. While statins are the fundamental component of this treatment, there is evidence supporting the use of ezetimibe, PCSK9 inhibitors, and ACL inhibitors as supplementary treatments to lower LDL cholesterol and the occurrence of MACE. In patients requiring or who have undergone PCI, recognizing the importance of statin, as well as integrating non-statin lipid-lowering agents, is essential for the proper implementation of lipid-lowering therapy to decrease future cardiovascular disease risk in these high-risk populations.

## DECLARATIONS

### Authors' contributions

Conceptualization, design, supervision, review, and revision of the manuscript: Mehran R  
Manuscript drafting and revision: Godfrey K, Patnaik S, Kim CJ

### Availability of data and materials

Not applicable.

### Financial support and sponsorship

Not applicable.

### Conflict of interest

Dr. Mehran R reports institutional research payments from Abbott, Abiomed, Alleviant Medical, AM-Pharma, Applied Therapeutics, Arena, AstraZeneca, BAIM, Bayer, Beth Israel Deaconess, Biosensors, Biotronik, Boston Scientific, Bristol-Myers Squibb, CardiaWave, CellAegis, CeloNova, CERC, Chiesi, Concept Medical, CSL Behring, DSI, Duke University, Element Science, Humacyte, Insel Gruppe AG, Janssen, Magenta, Medtronic, Novartis, OrbusNeich, Philips, Vivasure, Zoll; personal fees from Boston Scientific, California Institute for Regenerative Medicine (CIRM), Cine-Med Research, Janssen, WebMD; consulting fees paid to the institution from Idorsia Pharmaceuticals, Medtronic, Novartis, Philips; Equity < 1% in Applied Therapeutics, Elixir Medical, STEL, CONTROLRAD (spouse); Scientific Advisory Board for AMA, ACC (BOT Member), SCAI (Women in Innovations Committee Member), Biosensors (spouse); Faculty CRF (no fee). No other disclosures were reported. Other co-authors report no conflicts of interest.

### Ethical approval and consent to participate

Not applicable.

### Consent for publication

Not applicable.

### Copyright

© The Author(s) 2024.

## REFERENCES

1. WHO CVD Risk Chart Working Group. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. *Lancet Glob Health* 2019;7:e1332-45. DOI
2. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the

- GBD 2019 study. *J Am Coll Cardiol* 2020;76:2982-3021. DOI
3. Grundy SM, Feingold KR. Guidelines for the management of high blood cholesterol. In: Feingold KR, Anawalt B, Blackman MR, editors. Endotext South Dartmouth, MA: MDText.com, Inc.; 2000.
  4. Grundy SM, Feingold KR. Guidelines for the management of high blood cholesterol. 2022. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK305897/> [Last accessed on 3 Apr 2024].
  5. Feher MD. Lipid lowering to delay the progression of coronary artery disease. *Heart* 2003;89:451-8. DOI PubMed PMC
  6. Vaughan CJ, Gotto AM Jr, Basson CT. The evolving role of statins in the management of atherosclerosis. *J Am Coll Cardiol* 2000;35:1-10. DOI PubMed
  7. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. *JAMA* 2016;316:1289-97. DOI
  8. Fulcher J, O'Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. *Lancet* 2015;385:1397-405. DOI
  9. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. *J Am Coll Cardiol* 2019;73:e285-350. DOI
  10. Mach F, Baigent C, Catapano AL, et al. Corrigendum to: 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J* 2020;41:4255. DOI PubMed
  11. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and European atherosclerosis society (EAS). *Eur Heart J* 2020;41:111-88. DOI
  12. Qiao YN, Zou YL, Guo SD. Low-density lipoprotein particles in atherosclerosis. *Front Physiol* 2022;13:931931. DOI PubMed PMC
  13. Weitgasser R, Ratzinger M, Hemetsberger M, Siostrzonek P. LDL-cholesterin und kardiovaskuläre ereignisse: je niedriger desto besser? LDL-cholesterol and cardiovascular events: the lower the better. *Wien Med Wochenschr* 2018;168:108-20. DOI PubMed
  14. Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study. *J Am Coll Cardiol* 2015;65:1552-61. DOI PubMed PMC
  15. Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. *JAMA Cardiol* 2019;4:1287-95. DOI PubMed PMC
  16. Borén J, Williams KJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. *Curr Opin Lipidol* 2016;27:473-83. DOI PubMed
  17. Behbodikhah J, Ahmed S, Elyasi A, et al. Apolipoprotein B and Cardiovascular disease: biomarker and potential therapeutic target. *Metabolites* 2021;11:690. DOI PubMed PMC
  18. Han SH, Nicholls SJ, Sakuma I, Zhao D, Koh KK. Hypertriglyceridemia and cardiovascular diseases: revisited. *Korean Circ J* 2016;46:135-44. DOI PubMed PMC
  19. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. *Circulation* 2007;115:450-8. DOI
  20. Talmud PJ, Hawe E, Miller GJ, Humphries SE. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. *Arterioscler Thromb Vasc Biol* 2002;22:1918-23. DOI PubMed
  21. Navar AM. The evolving story of triglycerides and coronary heart disease risk. *JAMA* 2019;321:347-9. DOI PubMed
  22. Marston NA, Giugliano RP, Im K, et al. Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials. *Circulation* 2019;140:1308-17. DOI PubMed PMC
  23. Zhang BH, Yin F, Qiao YN, Guo SD. Triglyceride and triglyceride-rich lipoproteins in atherosclerosis. *Front Mol Biosci* 2022;9:909151. DOI PubMed PMC
  24. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med* 2019;380:11-22. DOI
  25. Yeshurun D, Gotto AM, Jr. Hyperlipidemia: perspectives in diagnosis and treatment. *South Med J* 1995;88:379-91. PubMed
  26. Gravina CF, Bertolami M, Rodrigues GH. Dyslipidemia: evidence of efficacy of the pharmacological and non-pharmacological treatment in the elderly. *J Geriatr Cardiol* 2012;9:83-90. DOI PubMed PMC
  27. Riccardi G, Giosuè A, Calabrese I, Vaccaro O. Dietary recommendations for prevention of atherosclerosis. *Cardiovasc Res* 2022;118:1188-204. DOI PubMed
  28. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. *JAMA* 1984;251:351-64. DOI PubMed
  29. Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). *Circulation* 1994;89:1333-445. DOI
  30. Chou R, Cantor A, Dana T, et al. Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US preventive services task force. *JAMA* 2022;328:754-71. DOI
  31. Naci H, Brughts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955

- participants from 135 randomized, controlled trials. *Circ Cardiovasc Qual Outcomes* 2013;6:390-9. DOI PubMed
32. Davidson MH, Robinson JG. Safety of aggressive lipid management. *J Am Coll Cardiol* 2007;49:1753-62. DOI PubMed
  33. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study (4S). *Lancet* 1994;344:1383-9. DOI PubMed
  34. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. *N Engl J Med* 1996;335:1001-9. DOI
  35. Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med* 1998;339:1349-57. DOI
  36. Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002;360:7-22. DOI
  37. Sato H, Kinjo K, Ito H, et al. Effect of early use of low-dose pravastatin on major adverse cardiac events in patients with acute myocardial infarction: the OACIS-LIPID Study. *Circ J* 2008;72:17-22. DOI
  38. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the national cholesterol educational program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and coronary-heart-disease evaluation (GREACE) study. *Curr Med Res Opin* 2002;18:220-8. DOI
  39. Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. *J Am College Cardiol* 2004;44:1772-9. DOI
  40. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med* 2005;352:1425-35. DOI
  41. Taguchi I, Iimuro S, Iwata H, et al. High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD): a randomized superiority trial. *Circulation* 2018;137:1997-2009. DOI
  42. Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The Antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). *JAMA* 2002;288:2998-3007. DOI
  43. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. *JAMA* 2005;294:2437-45. DOI
  44. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet* 2010;376:1670-81. DOI PubMed PMC
  45. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. *JAMA* 2004;291:1071-80. DOI
  46. Campeau L, Hunninghake DB, Knatterud GL, et al. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. *Circulation* 1999;99:3241-7. DOI
  47. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: arterial biology for the investigation of the treatment effects of reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. *Circulation* 2002;106:2055-60. DOI PubMed
  48. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. *Lancet* 2001;357:577-81. DOI
  49. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. *JAMA* 2001;285:1711-8. DOI
  50. Dohi T, Miyauchi K, Okazaki S, et al. Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): a follow-up study. *Atherosclerosis* 2010;210:497-502. DOI
  51. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. *JAMA* 2004;292:1307-16. DOI
  52. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med* 2004;350:1495-504. DOI
  53. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G; ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. *Circulation* 2004;110:674-8. DOI
  54. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. *J Am Coll Cardiol* 2007;49:1272-8. DOI
  55. Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (atorvastatin for reduction of myocardial damage during angioplasty) randomized trial. *J Am Coll Cardiol* 2009;54:558-65. DOI
  56. Kim JS, Kim J, Choi D, et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. *JACC Cardiovasc Interv* 2010;3:332-9. DOI

57. Briguori C, Visconti G, Focaccio A, et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. *J Am Coll Cardiol* 2009;54:2157-63. [DOI](#)
58. Sardella G, Conti G, Donahue M, et al. Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis: the ROMA trial. *Catheter Cardiovasc Interv* 2013;81:E36-43. [DOI](#)
59. Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study. *Circulation* 2004;110:1061-8. [DOI](#)
60. Dupuis J, Tardif JC, Cernacek P, Théroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. *Circulation* 1999;99:3227-33. [DOI](#) [PubMed](#)
61. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med* 2015;372:2387-97. [DOI](#)
62. Ouchi Y, Sasaki J, Arai H, et al. Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized, controlled trial. *Circulation* 2019;140:992-1003. [DOI](#) [PubMed](#)
63. Wilson PWF, Polonsky TS, Miedema MD, Khera A, Kosinski AS, Kuvin JT. Systematic review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. *Circulation* 2019;139:e1144-61. [DOI](#)
64. Ah YM, Jeong M, Choi HD. Comparative safety and efficacy of low- or moderate-intensity statin plus ezetimibe combination therapy and high-intensity statin monotherapy: a meta-analysis of randomized controlled studies. *PLoS One* 2022;17:e0264437. [DOI](#) [PubMed](#) [PMC](#)
65. Hu H, Shu T, Ma J, et al. Two novel disease-causing mutations in the LDLR of familial hypercholesterolemia. *Front Genet* 2021;12:762587. [DOI](#) [PubMed](#) [PMC](#)
66. Taranto MD, Giacobbe C, Fortunato G. Familial hypercholesterolemia: a complex genetic disease with variable phenotypes. *Eur J Med Genet* 2020;63:103831. [DOI](#) [PubMed](#)
67. Ji E, Lee S. Antibody-based therapeutics for atherosclerosis and cardiovascular diseases. *Int J Mol Sci* 2021;22:5770. [DOI](#) [PubMed](#) [PMC](#)
68. Manniello M, Pisano M. Alirocumab (praluent): first in the new class of PCSK9 inhibitors. *P T* 2016;41:28-53. [PMC](#)
69. Kasichayanula S, Grover A, Emery MG, et al. Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor. *Clin Pharmacokinet* 2018;57:769-79. [DOI](#) [PubMed](#) [PMC](#)
70. Guedeny P, Sorrentino S, Giustino G, et al. Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis. *Eur Heart J Cardiovasc Pharmacother* 2021;7:225-35. [DOI](#)
71. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med* 2017;376:1713-22. [DOI](#)
72. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med* 2018;379:2097-107. [DOI](#)
73. Kereiakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. *Am Heart J* 2015;169:906-15.e13. [DOI](#)
74. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. *N Engl J Med* 2015;372:1489-99. [DOI](#)
75. Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. *J Clin Lipidol* 2015;9:758-69. [DOI](#)
76. Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. *Eur Heart J* 2015;36:1186-94. [DOI](#) [PubMed](#) [PMC](#)
77. Ray KK, Leiter LA, Müller-Wieland D, et al. Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: the ODYSSEY DM-DYSLIPIDEMIA randomized trial. *Diabetes Obes Metab* 2018;20:1479-89. [DOI](#) [PubMed](#) [PMC](#)
78. Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. *JAMA* 2016;316:2373-84. [DOI](#)
79. Koskinas KC, Windecker S, Pedrazzini G, et al. Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS). *J Am Coll Cardiol* 2019;74:2452-62. [DOI](#)
80. Wang HF, Mao YC, Xu XY, et al. Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: a meta-analysis focusing on the number needed to treat. *Front Cardiovasc Med* 2022;9:1016802. [DOI](#) [PubMed](#) [PMC](#)
81. Toth PP, Worthy G, Gandra SR, et al. Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia. *J Am Heart Assoc* 2017;6. [DOI](#) [PubMed](#) [PMC](#)
82. Wang N, Tall AR. A new approach to PCSK9 therapeutics. *Circ Res* 2017;120:1063-5. [DOI](#) [PubMed](#) [PMC](#)
83. Kosmas CE, Muñoz Estrella A, Skavdis A, Peña Genao E, Martínez I, Guzmán E. Inclisiran for the treatment of cardiovascular

- disease: a short review on the emerging data and therapeutic potential. *Ther Clin Risk Manag* 2020;16:1031-7. DOI PubMed PMC
84. Nishikido T. Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease. *Cardiovasc Diabetol* 2023;22:20. DOI PubMed PMC
  85. Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. *N Engl J Med* 2020;382:1507-19. DOI
  86. Koenig W, Conde LG, Landmesser U, et al. Efficacy and safety of inclisiran in patients with polyvascular disease: pooled, post hoc analysis of the ORION-9, ORION-10, and ORION-11 phase 3 randomized controlled trials. *Cardiovasc Drugs Ther* 2022. DOI
  87. Brandts J, Ray KK. Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential. *Expert Opin Investig Drugs* 2020;29:763-70. DOI PubMed
  88. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. *N Engl J Med* 2023;388:1353-64. DOI
  89. Bazarbashi N, Miller M. Icosapent ethyl: niche drug or for the masses? *Curr Cardiol Rep* 2020;22:104. DOI
  90. Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. *Eur Heart J* 2020;41:3925-32. DOI PubMed PMC
  91. Borghi C, Bragagni A. Clinical results and mechanism of action of icosapent ethyl. *Eur Heart J Suppl* 2023;25:B37-40. DOI PubMed PMC
  92. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. *Circulation* 1998;98:2088-93. DOI PubMed
  93. Jakob T, Nordmann AJ, Schandelmaier S, Ferreira-González I, Briel M. Fibrates for primary prevention of cardiovascular disease events. *Cochrane Database Syst Rev* 2016;11:CD009753. DOI PubMed PMC
  94. Alder M, Bavishi A, Zumpf K, Peterson J, Stone NJ. A meta-analysis assessing additional LDL-C reduction from addition of a bile acid sequestrant to statin therapy. *Am J Med* 2020;133:1322-7. DOI PubMed
  95. Charles MA, Kane JP. New molecular insights into CETP structure and function: a review. *J Lipid Res* 2012;53:1451-8. DOI PubMed PMC
  96. Bowman L, Hopewell JC, Chen F, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. *N Engl J Med* 2017;377:1217-27. DOI
  97. Chambergo-Michilot D, Alur A, Kulkarni S, Agarwala A. Mipomersen in familial hypercholesterolemia: an update on health-related quality of life and patient-reported outcomes. *Vasc Health Risk Manag* 2022;18:73-80. DOI PubMed PMC
  98. Alonso R, Cuevas A, Mata P. Lomitapide: a review of its clinical use, efficacy, and tolerability. *Core Evid* 2019;14:19-30. DOI PubMed PMC
  99. Fogacci F, Ferri N, Toth PP, Ruscica M, Corsini A, Cicero AFG. Efficacy and safety of mipomersen: a systematic review and meta-analysis of randomized clinical trials. *Drugs* 2019;79:751-66. DOI PubMed
  100. Aastaneh B, Makhdami N, Aastaneh V, Guyatt G. The effect of mipomersen in the management of patients with familial hypercholesterolemia: a systematic review and meta-analysis of clinical trials. *J Cardiovasc Dev Dis* 2021;8:82. DOI PubMed PMC
  101. D'Erasmus L, Cefalù AB, Noto D, et al. Efficacy of lomitapide in the treatment of familial homozygous hypercholesterolemia: results of a real-world clinical experience in Italy. *Adv Ther* 2017;34:1200-10. DOI
  102. D'Erasmus L, Minicocci I, Nicolucci A, et al. Autosomal recessive hypercholesterolemia: long-term cardiovascular outcomes. *J Am Coll Cardiol* 2018;71:279-88. DOI
  103. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolemia: a single-arm, open-label, phase 3 study. *Lancet* 2013;381:40-6. DOI PubMed PMC
  104. van Lennep J, Averna M, Alonso R. Treating homozygous familial hypercholesterolemia in a real-world setting: experiences with lomitapide. *J Clin Lipidol* 2015;9:607-17. DOI
  105. D'Erasmus L, Steward K, Cefalù AB, et al. Efficacy and safety of lomitapide in homozygous familial hypercholesterolemia: the pan-European retrospective observational study. *Eur J Prev Cardiol* 2022;29:832-41. DOI
  106. Orringer CE, Jacobson TA, Saseen JJ, et al. Update on the use of PCSK9 inhibitors in adults: recommendations from an expert panel of the national lipid association. *J Clin Lipidol* 2017;11:880-90. DOI
  107. Grundy SM, Cleeman JJ, Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. *Circulation* 2004;110:227-39. DOI
  108. Nußbaumer B, Glechner A, Kaminski-Hartenthaler A, Mahlknecht P, Gartlehner G. Ezetimibe-statin combination therapy. *Dtsch Arztebl Int* 2016;113:445-53. DOI PubMed PMC
  109. Khan SU, Yedlapati SH, Lone AN, et al. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. *BMJ* 2022;377:e069116. DOI PubMed
  110. Kenneth R, Feingold M. Cholesterol lowering drugs. Endotext South Dartmouth, MA: MDTText.com, Inc.; 2000.
  111. Park IS, Lee SB, Song SH, et al. Ticagrelor-induced acute kidney injury can increase serum concentration of statin and lead to

- concurrency of rhabdomyolysis. *Anatol J Cardiol* 2018;19:225-6. [DOI](#) [PubMed](#) [PMC](#)
112. Newman CB. Safety of statins and nonstatins for treatment of dyslipidemia. *Endocrinol Metab Clin North Am* 2022;51:655-79. [DOI](#) [PubMed](#)
113. Hagiwara N, Kawada-Watanabe E, Koyanagi R, et al. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. *Eur Heart J* 2017;38:2264-76. [DOI](#) [PubMed](#) [PMC](#)